Compare Starbucks Corp (SBUX) vs BIO-TECHNE Corp (TECH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Starbucks Corp vs BIO-TECHNE Corp — how do they compare? Starbucks Corp trades at $93.16 (market cap $106.26B), while BIO-TECHNE Corp trades at $72.46 (market cap $11.36B). The key difference: Starbucks Corp is far larger — about 9.4× BIO-TECHNE Corp's market cap, and Starbucks Corp pays the higher dividend (2.7%). Which is the better fit depends on your goals — on Pluang, investors hold Starbucks Corp for 190 Days and BIO-TECHNE Corp for 63 Days on average.
| SBUX | TECH | |
|---|---|---|
Market Cap | $106.26B | $11.36B |
Volume | 30,248,434 | 5,390,331 |
Sector | Consumer Cyclical | Health |
52-Week High | $108.55 | $72.61 |
52-Week Low | $78.46 | $43.31 |
Typical Hold Time | 190 Days | 63 Days |
Enterprise Value | $125.08B | $11.39B |
Dividend Yield | 2.7% | 0.44% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Starbucks (SBUX) trades at $93.58, down 2.63% amid bearish technical signals and recent store closure announcements. The company shows mixed fundamentals with a high P/E ratio of 54.09 but strong recent earnings beats. Revenue growth remains modest at $37.18B for 2025, while net income declined to $1.86B. Analyst consensus remains positive with a $115.50 price target despite ongoing restructuring challenges and geopolitical tensions in China operations.
The stock faces near-term pressure from operational restructuring but maintains long-term growth potential through international expansion and brand strength. Key risks include labor relations, Chinese market exposure, and execution of store optimization strategy. With 47% analyst buy ratings and solid dividend payments, SBUX offers value for patient investors despite current headwinds.
TECH trades at $72.53, near its 52-week high of $72.70, with a bullish technical signal from moving averages. The company reported mixed quarterly earnings, beating in Q4 2025 and Q2 2026 but missing in Q1 2026. Revenue for 2025 was $1.22B, with a net income margin of 14.97%. Valuation ratios are elevated, with a P/E of 62.46 and P/S of 9.36. A significant development is the shareholder-approved acquisition by Merck KGaA at $73.00 per share, pending completion.
The outlook is heavily influenced by the pending acquisition, offering a near-term price ceiling. Fundamentals show solid profitability but high valuation multiples. Risks include acquisition deal completion uncertainty and integration challenges. Analyst sentiment is mixed with no sell ratings, but the consensus price target of $65.78 suggests limited upside from current levels, making the stock a hold pending acquisition closure.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Starbucks Corp
Starbucks Corporation retails, roasts, and provides its own brand of specialty coffee. The Company operates retail locations worldwide and sells whole bean coffees through its sales group, direct response business, supermarkets, and on the world wide web. Starbucks also produces and sells bottled coffee drinks and a line of ice creams.
Read more on SBUX →About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →
